非小细胞肺癌的化疗进展

Chemotherapy advances of non-small-cell lung cancer in the recent clinical trials

在中国,非小细胞肺癌是最常见的癌症致死原因之一,发病率也居高不下。诊断时,大部分病期晚,手术、放疗、化疗的远期获益有限。然而,新近有关化疗的临床试验却在不断的取得进展。本文综述非小细胞肺癌的辅助、新辅助、一线、二线化疗、老年或行为状态差的患者化疗进展。

Non - small - cell lung cancer （NSCLC） is the one of the leading causes of cancer mortality and also its incidence rate is constantly increasing in china. While diagnosing most of the patients present advanced stage, chemotherapy, surgery and radiation therapy have had a modest effect on patient outcomes. However, recent improvements have been seen in the latest clinical trials. The article will review the advances of adjuvant, neoadjuvant, the first - line, the second - line chemotherapy and the chemotherapy in the treatment of the patients with elder age or performance status 2.